RESIST-TB webinar: PHOENIx trial
RESIST-TB will host a webinar, Protecting MDR-TB and XDR-TB Affected Households: The PHOENIx MDR-TB Trial on Thursday, January 19th from 08:30 to 09:30 EST (13:30-14:30 CET, 14:30-15:30 SAST).
The Protecting Households On Exposure to Newly Diagnosed Index Multidrug-Resistant Tuberculosis Patients (PHOENIx) Study, is a phase III trial in development by the ACTG and IMPAACT networks aiming to asses the efficacy of six months of daily delamanid versus six months of isoniazid preventive therapy in high-risk household contacts of adult pulmonary MDR-TB cases.
For detailed information how to join the event, click here.
